ABIVAX Société Anonyme (0RA9.L)

EUR 5.15

(-2.65%)

Total Liabilities Summary of ABIVAX Société Anonyme

ABIVAX Société Anonyme's latest annual total liabilities in 2023 was 131.05 Million EUR , up 83.37% from previous year.
ABIVAX Société Anonyme's latest quarterly total liabilities in 2024 Q2 was 158.02 Million EUR , down 0.0% from previous quarter.
ABIVAX Société Anonyme reported annual total liabilities of 71.47 Million EUR in 2022, down -12.4% from previous year.
ABIVAX Société Anonyme reported annual total liabilities of 81.59 Million EUR in 2021, up 22.46% from previous year.
ABIVAX Société Anonyme reported quarterly total liabilities of 131.05 Million EUR for 2023 Q4, down 0.0% from previous quarter.
ABIVAX Société Anonyme reported quarterly total liabilities of 131.05 Million EUR for 2023 FY, up 83.37% from previous quarter.

Annual Total Liabilities Chart of ABIVAX Société Anonyme (2023 - 2013)

Historical Annual Total Liabilities of ABIVAX Société Anonyme (2023 - 2013)

Year	Total Liabilities	Total Liabilities Growth
2023	131.05 Million EUR	83.37%
2022	71.47 Million EUR	-12.4%
2021	81.59 Million EUR	22.46%
2020	66.62 Million EUR	66.78%
2019	39.94 Million EUR	105.98%
2018	19.39 Million EUR	244.17%
2017	5.63 Million EUR	45.23%
2016	3.88 Million EUR	-14.35%
2015	4.53 Million EUR	12.38%
2014	4.03 Million EUR	-9.29%
2013	4.44 Million EUR	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	158.02 Million EUR	0.0%
2023 Q4	131.05 Million EUR	0.0%
2023 FY	131.05 Million EUR	83.37%
2023 Q2	90.59 Million EUR	0.0%
2022 Q2	72.39 Million EUR	0.0%
2022 Q4	71.47 Million EUR	0.0%
2022 FY	71.47 Million EUR	-12.4%
2021 FY	81.59 Million EUR	22.46%
2021 Q2	59.56 Million EUR	0.0%
2021 Q4	81.59 Million EUR	0.0%
2020 FY	66.62 Million EUR	66.78%
2020 Q2	53.4 Million EUR	0.0%
2020 Q4	66.62 Million EUR	0.0%
2019 Q4	39.94 Million EUR	0.0%
2019 FY	39.94 Million EUR	105.98%
2019 Q2	39.62 Million EUR	0.0%
2018 Q2	4.95 Million EUR	0.0%
2018 FY	19.39 Million EUR	244.17%
2018 Q4	19.39 Million EUR	0.0%
2017 Q4	5.63 Million EUR	0.0%
2017 FY	5.63 Million EUR	45.23%
2017 Q2	4.01 Million EUR	0.0%
2016 Q4	3.88 Million EUR	0.0%
2016 Q2	3.79 Million EUR	0.0%
2016 FY	3.88 Million EUR	-14.35%
2015 Q4	4.53 Million EUR	0.0%
2015 FY	4.53 Million EUR	12.38%
2015 Q2	8.82 Million EUR	0.0%
2014 Q4	4.03 Million EUR	99924.57%
2014 Q3	4030.00 EUR	0.0%
2014 FY	4.03 Million EUR	-9.29%
2014 Q1	- EUR	0.0%
2013 FY	4.44 Million EUR	0.0%

Peer Total Liabilities Comparison of ABIVAX Société Anonyme

Name	Total Liabilities	Total Liabilities Difference
Boiron SA	198.7 Million EUR	34.046%
Laboratorios Farmaceuticos Rovi, S.A.	256.39 Million EUR	48.886%
Vetoquinol SA	165.12 Million EUR	20.633%
Valneva SE	341.14 Million EUR	61.585%
AB Science S.A.	46.5 Million EUR	-181.784%
Nanobiotix S.A.	95.74 Million EUR	-36.883%
PHAXIAM Therapeutics S.A.	25.69 Million EUR	-410.029%
Vivoryon Therapeutics N.V.	4.54 Million EUR	-2782.164%
BioSenic S.A.	32.26 Million EUR	-306.186%
Formycon AG	387.61 Million EUR	66.19%